期刊
FRONTIERS IN IMMUNOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.891274
关键词
SARS-CoV-2; COVID19; IEI; activated PI3K delta syndrome (APDS); monoclonal antibody; remdesivir; long-lasting infection; APDS
类别
资金
- Fondo 5x1000
This case demonstrates the good tolerability and efficacy of monoclonal antibodies in reducing viral shedding in long-lasting infections refractory to other treatments. The virus was cleared 7 days after monoclonal antibody administration, showing the effectiveness of this treatment option.
We described the case of a patient affected by activated PI3K-kinase delta syndrome (APDS) and a long-lasting and pauci-symptomatic SARS-CoV-2 infection, treated with multiple therapeutic agents including remdesivir and SARS-CoV-2-neutralizing monoclonal antibodies. We detected the clearance of the virus 105 days from the first positive swab and 7 days after monoclonal antibody administration. At genotyping, the SARS-CoV-2 virus resulted as wild type on all samples tested. This case shows the monoclonal antibodies' good tolerability and efficacy in reducing viral shedding in long-lasting infections refractory to other treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据